Charles Schwab Investment Management Inc. Decreases Stake in Akoya Biosciences, Inc. (NASDAQ:AKYA)

Charles Schwab Investment Management Inc. trimmed its position in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) by 64.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 63,002 shares of the company’s stock after selling 112,886 shares during the period. Charles Schwab Investment Management Inc. owned about 0.13% of Akoya Biosciences worth $171,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in shares of Akoya Biosciences by 16.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock valued at $158,000 after purchasing an additional 9,429 shares during the last quarter. Regal Investment Advisors LLC grew its stake in shares of Akoya Biosciences by 64.3% during the second quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock worth $44,000 after purchasing an additional 7,340 shares in the last quarter. Finally, GSA Capital Partners LLP increased its holdings in Akoya Biosciences by 87.4% in the third quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock valued at $845,000 after buying an additional 144,903 shares during the last quarter. Institutional investors and hedge funds own 79.42% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on AKYA shares. Craig Hallum cut Akoya Biosciences from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $7.00 to $5.00 in a research report on Friday, November 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price target (down from $4.00) on shares of Akoya Biosciences in a report on Tuesday, November 19th. Finally, Canaccord Genuity Group cut their price objective on shares of Akoya Biosciences from $6.00 to $3.50 and set a “buy” rating on the stock in a report on Friday, November 15th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.43.

Akoya Biosciences Price Performance

Shares of NASDAQ AKYA opened at $2.55 on Friday. The stock has a market cap of $126.39 million, a P/E ratio of -2.16 and a beta of 1.22. Akoya Biosciences, Inc. has a twelve month low of $1.88 and a twelve month high of $6.31. The stock has a 50 day moving average of $2.64 and a two-hundred day moving average of $2.50. The company has a current ratio of 2.75, a quick ratio of 1.85 and a debt-to-equity ratio of 5.62.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.